Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

2.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
3.

Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.

Cohen S, Waks Z, Elm JJ, Gordon MF, Grachev ID, Navon-Perry L, Fine S, Grossman I, Papapetropoulos S, Savola JM.

BMC Med Inform Decis Mak. 2018 Dec 20;18(1):138. doi: 10.1186/s12911-018-0714-7.

4.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
5.

Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.

Papapetropoulos S, Liu W, Duvvuri S, Thayer K, Gray DL.

Neurodegener Dis. 2018;18(5-6):262-269. doi: 10.1159/000492498. Epub 2018 Nov 19.

PMID:
30453303
6.

Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.

Krismer F, Seppi K, Wenning GK, Papapetropoulos S, Abler V, Goebel G, Schocke M, Poewe W.

Parkinsonism Relat Disord. 2019 Jan;58:23-27. doi: 10.1016/j.parkreldis.2018.08.004. Epub 2018 Aug 7.

PMID:
30145124
7.

Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.

Schneider F, Erisson L, Beygi H, Bradbury M, Cohen-Barak O, Grachev ID, Guzy S, Loupe PS, Levi M, McDonald M, Savola JM, Papapetropoulos S, Tracewell WG, Velinova M, Spiegelstein O.

Br J Clin Pharmacol. 2018 Oct;84(10):2422-2432. doi: 10.1111/bcp.13702. Epub 2018 Aug 9.

8.

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vitolo OV, Wang J, Miller BM, Kaye JA.

Nat Rev Drug Discov. 2017 Oct;16(10):736. doi: 10.1038/nrd.2017.153. Epub 2017 Sep 22. No abstract available.

PMID:
28935908
9.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.

J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241.

PMID:
28826192
10.

Biometric Digital Health Technology for Measuring Motor Function in Parkinson's Disease: Results from a Feasibility and Patient Satisfaction Study.

Mitsi G, Mendoza EU, Wissel BD, Barbopoulou E, Dwivedi AK, Tsoulos I, Stavrakoudis A, Espay AJ, Papapetropoulos S.

Front Neurol. 2017 Jun 13;8:273. doi: 10.3389/fneur.2017.00273. eCollection 2017.

11.

Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action.

Hirsch IB, Martinez J, Dorsey ER, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S.

Clin Ther. 2017 May;39(5):1064-1076. doi: 10.1016/j.clinthera.2017.03.018. Epub 2017 Apr 14.

12.

Drug repurposing from the perspective of pharmaceutical companies.

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D.

Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Review.

13.

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.

Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652.

14.

Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.

Krismer F, Seppi K, Wenning GK, Abler V, Papapetropoulos S, Poewe W.

Mov Disord. 2016 Oct;31(10):1577-1581. doi: 10.1002/mds.26743.

PMID:
27474888
15.

Technology in Parkinson's disease: Challenges and opportunities.

Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology.

Mov Disord. 2016 Sep;31(9):1272-82. doi: 10.1002/mds.26642. Epub 2016 Apr 29. Review.

17.

Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?

Papapetropoulos S, Mitsi G, Espay AJ.

Front Neurol. 2015 Feb 26;6:34. doi: 10.3389/fneur.2015.00034. eCollection 2015. Review. No abstract available.

18.

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL.

JAMA Neurol. 2014 Dec;71(12):1520-8. doi: 10.1001/jamaneurol.2014.1954.

PMID:
25322077
19.

Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention.

Wissel J, Verrier M, Simpson DM, Charles D, Guinto P, Papapetropoulos S, Sunnerhagen KS.

PM R. 2015 Jan;7(1):60-7. doi: 10.1016/j.pmrj.2014.08.946. Epub 2014 Aug 27. Review.

PMID:
25171879
20.

Descriptive epidemiology of cervical dystonia.

Defazio G, Jankovic J, Giel JL, Papapetropoulos S.

Tremor Other Hyperkinet Mov (N Y). 2013 Nov 4;3. pii: tre-03-193-4374-2. doi: 10.7916/D80C4TGJ. eCollection 2013.

21.

OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review.

Nalysnyk L, Papapetropoulos S, Rotella P, Simeone JC, Alter KE, Esquenazi A.

BMC Neurol. 2013 Sep 8;13:118. doi: 10.1186/1471-2377-13-118. Review.

22.

Biomarkers associated with migraine and their potential role in migraine management.

Durham P, Papapetropoulos S.

Headache. 2013 Sep;53(8):1262-77. doi: 10.1111/head.12174. Epub 2013 Jul 12. Review.

PMID:
23848170
23.

Effects of switching acute treatment on disability in migraine patients using triptans.

Serrano D, Buse DC, Kori SH, Papapetropoulos S, Cunanan CM, Manack AN, Reed ML, Lipton RB.

Headache. 2013 Oct;53(9):1415-29. doi: 10.1111/head.12164. Epub 2013 Jun 28.

PMID:
23808937
24.

An accelerometry-based study of lower and upper limb tremor in Parkinson's disease.

Scanlon BK, Levin BE, Nation DA, Katzen HL, Guevara-Salcedo A, Singer C, Papapetropoulos S.

J Clin Neurosci. 2013 Jun;20(6):827-30. doi: 10.1016/j.jocn.2012.06.015. Epub 2013 Apr 29.

PMID:
23639618
25.

Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications.

Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL.

Cephalalgia. 2013 Apr;33(6):408-15. doi: 10.1177/0333102412473371. Epub 2013 Mar 5. Review.

26.

Psychiatric comorbidities of episodic and chronic migraine.

Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB.

J Neurol. 2013 Aug;260(8):1960-9. doi: 10.1007/s00415-012-6725-x. Epub 2012 Nov 7. Review.

PMID:
23132299
27.

Statistical analysis and mapping of the Unified Parkinson's Disease Rating Scale to Hoehn and Yahr staging.

Tsanas A, Little MA, McSharry PE, Scanlon BK, Papapetropoulos S.

Parkinsonism Relat Disord. 2012 Jun;18(5):697-9. doi: 10.1016/j.parkreldis.2012.01.011. Epub 2012 Feb 7. No abstract available.

PMID:
22321863
28.

An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.

Wider C, Ross OA, Nishioka K, Heckman MG, Vilariño-Güell C, Jasinska-Myga B, Erketin-Taner N, Rademakers R, Graff-Radford NR, Mash DC, Papapetropoulos S, Duara R, Uchikado H, Wszolek ZK, Farrer MJ, Dickson DW.

J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):424-9. doi: 10.1136/jnnp-2011-301413. Epub 2012 Jan 30.

29.

Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.

Papapetropoulos SS.

CNS Neurosci Ther. 2012 May;18(5):380-7. doi: 10.1111/j.1755-5949.2011.00253.x. Epub 2011 Jun 7. Review.

PMID:
22070400
30.

β-N-methylamino-L-alanine induces neurological deficits and shortened life span in Drosophila.

Zhou X, Escala W, Papapetropoulos S, Zhai RG.

Toxins (Basel). 2010 Nov;2(11):2663-79. doi: 10.3390/toxins2112663. Epub 2010 Nov 3.

31.

Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).

Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S.

BMC Neurol. 2011 Nov 4;11:140. doi: 10.1186/1471-2377-11-140.

32.

MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy.

Vilariño-Güell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, Pahwa R, Lyons KE, Uitti RJ, Wszolek ZK, Dickson DW, Farrer MJ, Ross OA.

Neurology. 2011 Feb 15;76(7):670-2. doi: 10.1212/WNL.0b013e31820c30c1. No abstract available.

33.

Objective quantification of neuromotor symptoms in Parkinson's disease: implementation of a portable, computerized measurement tool.

Papapetropoulos S, Katzen HL, Scanlon BK, Guevara A, Singer C, Levin BE.

Parkinsons Dis. 2010 Jun 30;2010:760196. doi: 10.4061/2010/760196.

34.

Glucocerebrosidase mutations in diffuse Lewy body disease.

Nishioka K, Ross OA, Vilariño-Güell C, Cobb SA, Kachergus JM, Mann DM, Snowden J, Richardson AM, Neary D, Robinson CA, Rajput A, Papapetropoulos S, Mash DC, Pahwa R, Lyons KE, Wszolek ZK, Dickson DW, Farrer MJ.

Parkinsonism Relat Disord. 2011 Jan;17(1):55-7. doi: 10.1016/j.parkreldis.2010.09.009.

35.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

36.

Multi-modal hallucinations and cognitive function in Parkinson's disease.

Katzen H, Myerson C, Papapetropoulos S, Nahab F, Gallo B, Levin B.

Dement Geriatr Cogn Disord. 2010;30(1):51-6. doi: 10.1159/000314875. Epub 2010 Jul 31.

37.

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers.

Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O'Neill G.

Clin Neuropharmacol. 2010 Mar-Apr;33(2):55-60. doi: 10.1097/WNF.0b013e3181d137d2.

PMID:
20375654
38.

SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Shehadeh LA, Yu K, Wang L, Guevara A, Singer C, Vance J, Papapetropoulos S.

PLoS One. 2010 Feb 8;5(2):e9104. doi: 10.1371/journal.pone.0009104.

39.

Melatonin MT1 and MT2 receptor expression in Parkinson's disease.

Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S.

Med Sci Monit. 2010 Feb;16(2):BR61-7.

PMID:
20110911
40.

BMAA neurotoxicity in Drosophila.

Zhou X, Escala W, Papapetropoulos S, Bradley WG, Zhai RG.

Amyotroph Lateral Scler. 2009;10 Suppl 2:61-6. doi: 10.3109/17482960903273445.

PMID:
19929734
41.

Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.

Plaitakis A, Latsoudis H, Kanavouras K, Ritz B, Bronstein JM, Skoula I, Mastorodemos V, Papapetropoulos S, Borompokas N, Zaganas I, Xiromerisiou G, Hadjigeorgiou GM, Spanaki C.

Eur J Hum Genet. 2010 Mar;18(3):336-41. doi: 10.1038/ejhg.2009.179. Epub 2009 Oct 14.

42.

GCH1 expression in human cerebellum from healthy individuals is not gender dependent.

Wider C, Lincoln S, Dachsel JC, Kapatos G, Heckman MG, Diehl NN, Papapetropoulos S, Mash D, Rajput A, Rajput AH, Dickson DW, Wszolek ZK, Farrer MJ.

Neurosci Lett. 2009 Oct 2;462(1):73-5. doi: 10.1016/j.neulet.2009.06.082. Epub 2009 Jun 30.

43.

Botulinum toxin type a for painful limbs moving extremities.

Argyriou AA, Papapetropoulos S.

Mov Disord. 2010 Jan 15;25(1):125. doi: 10.1002/mds.22602. No abstract available.

PMID:
19425081
44.

Contemporary Encephalitis Lethargica: phenotype, laboratory findings and treatment outcomes.

Lopez-Alberola R, Georgiou M, Sfakianakis GN, Singer C, Papapetropoulos S.

J Neurol. 2009 Mar;256(3):396-404. doi: 10.1007/s00415-009-0074-4. Epub 2009 Mar 6.

PMID:
19412724
45.

Hemifacial spasm and pontine compression caused by a giant vertebrobasilar dolichoectasia.

Papapetropoulos S, Argyriou AA, Guevara A, Sengun C, Mitsi G, Singer C.

Cerebrovasc Dis. 2009;27(4):413-4. doi: 10.1159/000209243. Epub 2009 Mar 18. No abstract available.

46.

Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease.

Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC.

Acta Neurol Scand. 2009 Oct;120(4):216-25. doi: 10.1111/j.1600-0404.2008.01150.x. Epub 2009 Feb 26.

PMID:
19254284
47.

Subthreshold depression in Parkinson's disease.

Nation DA, Katzen HL, Papapetropoulos S, Scanlon BK, Levin BE.

Int J Geriatr Psychiatry. 2009 Sep;24(9):937-43. doi: 10.1002/gps.2199.

48.

FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.

Wider C, Dachsel JC, Soto AI, Heckman MG, Diehl NN, Yue M, Lincoln S, Aasly JO, Haugarvoll K, Trojanowski JQ, Papapetropoulos S, Mash D, Rajput A, Rajput AH, Gibson JM, Lynch T, Dickson DW, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Mov Disord. 2009 Feb 15;24(3):455-9. doi: 10.1002/mds.22442.

49.

Objective tremor registration during DBS surgery for essential tremor.

Papapetropoulos S, Gallo BV, Guevara A, Singer C, Mitsi G, Lyssikatos C, Jagid JR.

Clin Neurol Neurosurg. 2009 May;111(4):376-9. doi: 10.1016/j.clineuro.2008.10.017. Epub 2009 Jan 3.

PMID:
19121890
50.

Sarcoidosis with basal ganglial infiltration presenting as Parkinsonism.

Papapetropoulos S, Guevara A, Georgiou M, Mitsi G, Singer C, Delgado S.

BMJ Case Rep. 2009;2009. pii: bcr07.2008.0569. doi: 10.1136/bcr.07.2008.0569. Epub 2009 Mar 17.

Supplemental Content

Loading ...
Support Center